The debate over the ideal frequency of pharmaceutical sales calls has persisted for years. While traditional strategies emphasize quantity and maximizing in-person visits, the modern healthcare landscape calls for a more strategic and flexible approach.
Historically, pharmaceutical sales representatives aimed to pack their schedules with 8–10 in-person meetings daily. The rationale was straightforward: the more in-person interactions, the higher the likelihood of driving prescriptions. However, this volume-driven model is becoming increasingly outdated in today's rapidly changing healthcare environment.
A Strategic Approach to Call Frequency
Limited Access
Physicians face increasing time pressures and administrative responsibilities, making frequent in-person meetings more challenging than ever. Over the past decade, studies have repeatedly shown a steady decline in access to pharmaceutical sales representatives.¹
On average, sales calls last only 5–10 minutes, underscoring the need for concise, impactful communication.²
Digital Channels
The emergence of digital communication has created new opportunities for engaging healthcare professionals (HCPs). Industry reports reveal a growing trend among pharmaceutical companies toward virtual meetings and using online content to inform and build relationships.³
Value-Driven Interactions
Healthcare professionals (HCPs) now prioritize engagements that provide meaningful insights and directly contribute to patient care. Research shows that many physicians prefer email as a communication channel, highlighting the growing importance of digital touchpoints.⁴
In today's dynamic healthcare landscape, success hinges on striking the right balance between in-person and digital interactions. Emerging technologies, such as AI-powered platforms like reprai, are reshaping how pharmaceutical companies engage with HCPs. These tools enable 24/7 access to information, deliver personalized content, and create virtual engagement opportunities, enhancing both the frequency and quality of communication.
By leveraging technology and embracing innovative, value-driven strategies, pharmaceutical companies can navigate the complexities of modern HCP engagement. A digital-first approach will not only adapt to evolving trends but also ensure stronger, more meaningful connections with healthcare professionals, empowering them to deliver better patient care.
Sources
1. ZS Associates AccessMonitor™ (zs.com)
2. Pharmaceutical Executive (pharmexec.com)
3. Veeva, Digital Trends in the Life Sciences Industry, 2023
4. DRG Digital, "ePharma Physician® Report", 2021